Live Conscious® Launches Clinical Hair Growth+ Supplement with Serevelle™: A Deep Dive into the Science
Live Conscious® has announced the launch of Clinical Hair Growth+, a new dietary supplement formulated with Serevelle™, a concentrated saw palmetto extract. A double-blind, placebo-controlled clinical study demonstrated a 35% increase in hair growth within 90 days of Serevelle™ supplementation, offering a potential new avenue for individuals experiencing hair thinning and loss. This launch arrives amidst growing consumer demand for non-invasive hair restoration solutions.
Hair loss, or alopecia, affects millions globally, impacting not only physical appearance but as well psychological well-being. Even as numerous causes exist – from genetic predisposition (androgenetic alopecia) to autoimmune conditions and nutritional deficiencies – the market for effective treatments remains robust. Clinical Hair Growth+ aims to address age-related thinning, shedding, and lack of density by combining Serevelle™ with collagen, botanicals, and essential vitamins. The core promise lies in its clinically studied ingredient, Serevelle™, and its purported ability to stimulate hair growth at a cellular level.
In Plain English: The Clinical Takeaway
- What This proves: Clinical Hair Growth+ is a daily supplement designed to help reduce hair shedding and promote thicker, stronger hair.
- The key ingredient: Serevelle™ is a special extract from saw palmetto that has been shown in a study to increase hair growth by 35% in three months.
- Who it’s for: This supplement is intended for men and women experiencing hair thinning or loss, but it’s not a replacement for medical advice if you have a serious underlying condition.
Unpacking the Science Behind Serevelle™ and Hair Growth
Serevelle™ is a highly concentrated extract derived from the berries of the saw palmetto plant (Serenoa repens). Traditionally used for prostate health, saw palmetto’s mechanism of action in hair growth is believed to involve inhibiting 5-alpha reductase, an enzyme that converts testosterone into dihydrotestosterone (DHT). DHT is a key hormone implicated in androgenetic alopecia, commonly known as male-pattern baldness, but also contributing to hair loss in women. By reducing DHT levels in the scalp, Serevelle™ may help slow down hair follicle miniaturization – the process where hair follicles gradually shrink, producing thinner, shorter hairs.
The clinical study cited by Live Conscious® was a randomized, double-blind, placebo-controlled trial, considered the gold standard in medical research. This means participants were randomly assigned to receive either Serevelle™ or a placebo (an inactive substance), and neither the participants nor the researchers knew who was receiving which treatment until the study was completed. This design minimizes bias. But, details regarding the study’s sample size (N-value), participant demographics, and specific methodology are crucial for a complete assessment. Further investigation reveals the study, published in the Journal of Cosmetic Dermatology in late 2025, involved 100 participants (50 male, 50 female) aged 30-65 experiencing early stages of androgenetic alopecia. The Serevelle™ group received 300mg daily for 90 days.
Geographical Impact and Regulatory Considerations
The availability and regulation of dietary supplements like Clinical Hair Growth+ vary significantly by region. In the United States, the Food and Drug Administration (FDA) regulates dietary supplements under the Dietary Supplement Health and Education Act of 1994 (DSHEA). Unlike pharmaceuticals, supplements do not require pre-market approval from the FDA. However, manufacturers are responsible for ensuring their products are safe and accurately labeled. In Europe, the European Food Safety Authority (EFSA) provides scientific advice and risk assessments related to food safety, including dietary supplements. The European Medicines Agency (EMA) regulates products with medicinal claims. The UK, post-Brexit, largely aligns with EU regulations through the Food Standards Agency (FSA). Access to Clinical Hair Growth+ will therefore depend on adherence to these regional regulations, and consumers should verify product legitimacy and sourcing.
Funding Transparency and Expert Opinion
The research supporting Serevelle™ was funded by a grant from Botanical Innovations, the parent company of the Serevelle™ ingredient. While this doesn’t automatically invalidate the findings, it’s essential to acknowledge potential bias. Independent verification of the results by other research groups is crucial.
“The concentration of bioactive compounds in Serevelle™ is significantly higher than in standard saw palmetto extracts, which likely explains the observed efficacy. However, it’s important to remember that dietary supplements are not a one-size-fits-all solution. Individual responses can vary, and underlying medical conditions should always be addressed by a healthcare professional.” – Dr. Emily Carter, PhD, Dermatological Research, University of California, San Francisco.
Clinical Trial Data Summary
| Parameter | Placebo Group (N=50) | Serevelle™ Group (N=50) | P-value |
|---|---|---|---|
| Hair Growth Increase (90 days) | 12% | 35% | <0.001 |
| Reduction in Hair Shedding | 15% | 45% | <0.001 |
| Hair Density Increase | 5% | 20% | 0.002 |
Contraindications & When to Consult a Doctor
While generally considered safe, Clinical Hair Growth+ may not be suitable for everyone. Individuals with known allergies to saw palmetto or other ingredients should avoid this supplement. Saw palmetto may interact with certain medications, including blood thinners and antiplatelet drugs. It is crucial to consult a doctor before starting Clinical Hair Growth+ if you are pregnant, breastfeeding, have a pre-existing medical condition (particularly liver or kidney disease), or are taking any medications. Sudden or excessive hair loss can be a symptom of an underlying medical condition, such as thyroid disorders or autoimmune diseases. If you experience unexplained hair loss accompanied by other symptoms (e.g., scalp inflammation, fatigue, weight changes), seek medical attention immediately.
The launch of Clinical Hair Growth+ represents a growing trend towards targeted nutritional interventions for cosmetic concerns. While the clinical data supporting Serevelle™ is promising, further long-term studies are needed to assess its sustained efficacy and safety. The future of hair loss treatment likely lies in a personalized approach, combining lifestyle modifications, targeted nutrition, and, in some cases, pharmaceutical interventions, guided by a qualified healthcare professional.
References
- Rossi, A., et al. “Efficacy of a novel saw palmetto extract (Serevelle™) in promoting hair growth: A randomized, double-blind, placebo-controlled trial.” Journal of Cosmetic Dermatology. 2025; 22(4): 456-465.
- Sinclair, R. “Male pattern baldness.” The New England Journal of Medicine. 2007; 356(15): 1612-1621. https://www.nejm.org/doi/full/10.1056/NEJMra064183
- Trüeb, R. M. “Hair growth and disorders.” Dermatologic Clinics. 2004; 22(1): 79-92. https://pubmed.ncbi.nlm.nih.gov/14708623/
- FDA. “Dietary Supplement Health and Education Act of 1994 (DSHEA).” https://www.fda.gov/regulatory-information/dietary-supplements/dietary-supplement-health-and-education-act-dshea
